HIPK2 and Hyperglycemia: The above findings highlight how metabolic conditions such as hyperglycemia might reduce the response to anticancer therapies by impairing the apoptotic activity of the HIPK2/p53 axis, in agreement with preclinical studies showing a reduction of chemotherapy cytotoxicity by hyperglycemia [86].